Company profile
Tonix Pharmaceuticals Holding Corp.
NASDAQ:TNXPBiotechnology: Pharmaceutical Preparations
Drug pipeline (5)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| CYCLOBENZAPRINE HYDROCHLORIDE | approved | — | 0 | — |
| Sumatriptan | approved | — | 8 | approved |
| Sumatriptan Succinate | approved | — | 7 | approved |
| DEXISOMETHEPTENE MUCATE | phase2 | — | 2 | no active trials |
| Oxytocin | phase2 | — | 1 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (34)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02015234 | phase3 | completed | 2013-12-01 | 2015-08-01 | Tonix Pharmaceuticals, Inc. | 12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients |
| NCT03110575 | phase3 | terminated | 2017-06-20 | 2018-07-27 | Tonix Pharmaceuticals, Inc. | 12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients |
| NCT02589275 | phase3 | completed | 2015-08-04 | 2016-09-28 | Tonix Pharmaceuticals, Inc. | A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients |
| NCT03508700 | phase3 | completed | 2018-04-19 | 2019-09-30 | Tonix Pharmaceuticals, Inc. | A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD |
| NCT01490788 | phase1 | completed | 2011-11-18 | 2011-12-30 | Tonix Pharmaceuticals, Inc. | A Comparative Bioavailability and Pharmacokinetic Study of TNX-102 2.4 mg and Cyclobenzaprine 5 mg Tablets in Healthy Adults. |
FDA applications (3)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 208223 | NDA | TONIX MEDICINES INC | ||||
Loading… | ||||||
| NDA 210884 | NDA | TONIX MEDICINES INC | ||||
Loading… | ||||||
| NDA 219428 | NDA | TONIX PHARMACEUTICALS INC | ||||
Loading… | ||||||